ADCP Bioassay Effector Cell FcγRIa-NFAT/Jurkat
CBP74105
詢 價(jià)
索取Protocol
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. Background | |
|
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. |
|
| II. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIa_NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| IV.Representative Data | |
Figure 1. Dose response of Rituximab in ADCP Bioassay Effector Cell FcyRⅠa/NFAT Reporter-Jurkat (C11)，the EC50 was 1.94ng/ml.Raji cells as target cells.
